Your Health. Your Family. Your Choice.
Administered by: Unknown Purchased by: Unknown
Life Threatening? No
Write-up: Initial case was received from a health care professional via Sales representative on 17 March 2014. A 13-months-old female patient whose medical history and concomitant medication was not reported had received MENACTRA (dose, route and anatomical site of administration not reported) on 30 October 2013. On 25 February 2014, the patient was admitted to the hospital. The patient started treatment with suspected upper respiratory tract infection after the throat culture (the result of throat culture was not reported). On 26 February 2014, she was admitted to the private hospital and was transferred to Hospital with suspected meningococcal meningitis for the reason that the patient had an eruption. The patient was closely monitored by the reporting physician in the pediatric intensive care unit. The blood was closely monitored by the reporting physician in the pediatric intensive care unit. The blood and cerebrospinal fluid samples were collected from the patient. However the reporter physician could not provide the results of test. The patient died on 04 March 2014. Comment: This case could not be considered as the lack of efficacy. Because, MENACTRA is indicated in children aged from 12 months to 15 years as two doses (three months apart) according to our local labeling information. However, MENACTRA was administered to the patient as a single dose. The list of documents held by sender: None.
Copyright © 2020 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166